试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
编号:NCT01651936登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:MK-8457 100 mg、Methotrexate、Dose-match placebo
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
编号:NCT01946152登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Dexamethasone、Filgrastim-sndz、Laboratory Biomarker Analysis、Pomalidomide
登记的停止原因(原文):Per PI at time of CR
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas
编号:NCT03158116登记状态:提前终止企业 / 申办者:UCSF Benioff Children's Hospital Oakland
药物 / 成分:Inhaled Aztreonam
登记的停止原因(原文):IRB application expired.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
编号:NCT03326674登记状态:提前终止企业 / 申办者:Odonate Therapeutics, Inc.
药物 / 成分:Tesetaxel and Capecitabine、Capecitabine
登记的停止原因(原文):The Sponsor has discontinued the development of tesetaxel
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
编号:NCT03858972登记状态:提前终止企业 / 申办者:Odonate Therapeutics, Inc.
药物 / 成分:Tesetaxel、Capecitabine
登记的停止原因(原文):The Sponsor has discontinued the development of tesetaxel
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
编号:NCT03952325登记状态:提前终止企业 / 申办者:Odonate Therapeutics, Inc.
药物 / 成分:Tesetaxel、Tesetaxel、Tesetaxel、Nivolumab
登记的停止原因(原文):The Sponsor has discontinued the development of tesetaxel
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-30
A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants
编号:NCT04202497登记状态:提前终止企业 / 申办者:Takeda
药物 / 成分:TAK-418、[18F]MNI-1054 (radiotracer)
登记的停止原因(原文):Study was prematurely terminated because of administrative reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-29
The Effect of Selenium Supplementation Among Pediatric Patients With Burns
编号:NCT00860379登记状态:提前终止企业 / 申办者:Shriners Hospitals for Children
药物 / 成分:Selenium1、Selenium2、Placebo
登记的停止原因(原文):Due to a shift in primary responsibilities, the PI was not longer able to enroll subjects.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-29
Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)
编号:NCT01440062登记状态:提前终止企业 / 申办者:Charite University, Berlin, Germany
药物 / 成分:Verum arm receiving Vitamin D oil、low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-07-29
MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
编号:NCT01647880登记状态:提前终止企业 / 申办者:Charite University, Berlin, Germany
药物 / 成分:Verum arm receiving Gilenya®、Active Comparator receiving Extavia®
登记的停止原因(原文):delayed recruitment
查看官方原始记录 ↗